Australian recommendations for the management of drug-resistant tuberculosis, 2023
DOI:
https://doi.org/10.33321/cdi.2023.47.48%20Abstract
Disclaimer: The views expressed in this item are those of the individual authors, and do not necessarily represent the views of the Communicable Diseases Intelligence journal or the Australian Centre for Disease Control. While this Policy and Guidelines item was drafted with consideration to the then-available information on the condition(s) addressed within, it may not be complete and may not represent the currently understood best practice for the referenced condition(s). Readers are advised to refer to the most recent guidance on this matter, where such guidance exists and where its authoritativeness can be established. These guidelines do not replace the need for clinical judgment to be exercised for each individual circumstance, nor the necessity for expert advice to be obtained as appropriate.
Downloads
References
World Health Organization (WHO) Global Tuberculosis Programme. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment, 2022 update. Geneva: WHO; 15 December 2022. Available from: https://www.who.int/publications/i/item/9789240063129.
WHO Global Tuberculosis Programme. Rapid Communication: key changes to the treatment of drug-resistant tuberculosis. Geneva: WHO; 2 May 2022. Available from: https://www.who.int/publications/i/item/WHO-UCN-TB-2022-2.
WHO Global Tuberculosis Programme. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment. Geneva: WHO; 15 June 2020. Available from: https://www.who.int/publications/i/item/9789240007048.
WHO. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: WHO; 2019. Available from: https://apps.who.int/iris/handle/10665/311389.
Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019;200(10):e93–142. doi: https://doi.org/10.1164/rccm.201909-1874ST.
WHO Global Tuberculosis Programme. WHO consolidated guidelines on tuberculosis: module 5: management of tuberculosis in children and adolescents. Geneva: WHO; 18 March 2022. Available from: https://www.who.int/publications/i/item/9789240046764.
The Sentinel Project on Pediatric Drug-Resistant Tuberculosis. Management of Drug-Resistant Tuberculosis in Children: A Field Guide. November 2021, Fifth edition. Boston: The Sentinel Project on Pediatric Drug-Resistant Tuberculosis; November 2021. Available from: http://sentinel-project.org/wp-content/uploads/2022/03/DRTB-Field-Guide-2021_v5.pdf.
Brode SK, Dwilow R, Kunimoto D, Menzies D, Khan FA. Canadian Tuberculosis Standards – 8th Edition, Chapter 8: Drug-resistant tuberculosis. Can J Respir. 2022;6(Suppl 1):109–128. doi: https://doi.org/10.1080/24745332.2022.2039499.
Nyang’wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z et al. A 24-week, all-oral regimen for rifampicin-resistant tuberculosis. N Engl J Med. 2022;387(25):2331–43. doi: https://doi.org/10.1056/NEJMoa2117166.
Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893–902. doi: https://doi.org/10.1056/NEJMoa1901814.
Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N et al. Bedaquiline–pretomanid–linezolid regimens for drug-resistant tuberculosis. N Engl J Med. 2022;387(9):810–23. doi: https://doi.org/10.1056/NEJMoa2119430.
WHO Global Tuberculosis Programme. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. Geneva: WHO; 2008. Available from: https://apps.who.int/iris/handle/10665/43965.
WHO Global Tuberculosis Programme. Guidelines for the programmatic management of drug-resistant tuberculosis - 2011 update. Geneva: WHO; 15 February 2011. Available from: https://www.who.int/publications/i/item/9789241501583.
WHO Global Tuberculosis Programme. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. Geneva: WHO; 16 September 2016. Available from: https://www.who.int/publications/i/item/9789241549639.
WHO Global Tuberculosis Programme. Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis, 27–29 October 2020. Geneva: WHO; 22 January 2021. Available from: https://www.who.int/publications/i/item/9789240018662.
WHO Global Tuberculosis Programme. Global tuberculosis report 2022. Geneva: WHO; 27 October 2022. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022.
WHO Global Tuberculosis Programme. Global tuberculosis report 2020. Geneva: WHO; 15 October 2020. Available from: https://www.who.int/publications/i/item/9789240013131.
Australian Government Department of Health and Aged Care, National Notifiable Diseases Surveillance System (NNDSS). Tuberculosis notifications, 2019–2022. [Unpublished data.] Canberra: Australian Government Department of Health and Aged Care. [Accessed on 16 June 2023.]
Bastian I, Shephard L, Lumb R, National Tuberculosis Advisory Committee. Revised guidelines for Australian laboratories performing mycobacteriology testing. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.2.
van der Werf MJ, Hollo V, Ködmön C, Dara M, Catchpole M. Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union. Eur Respir J. 2017;49(3):1601992. doi: https://doi.org/10.1183/13993003.01992-2016.
Tsang CA, Shah N, Armstrong LR, Marks SM. Eligibility for a shorter treatment regimen for multidrug-resistant tuberculosis in the United States, 2011–2016. Clin Infect Dis. 2019;70(5):907–16. doi: https://doi.org/10.1093/cid/ciz263.
Lange C, Duarte R, Fre´chet-Jachym M, Guenther G, Guglielmetti L, Olaru ID et al. Limited benefit of the new shorter multidrug-resistant tuberculosis regimen in Europe. Am J Respir Crit Care Med. 2016;194(8):1029–31. doi: https://doi.org/10.1164/rccm.201606-1097LE.
Van Deun A, Decroo T, Piubello A, de Jong BC, Lynen L, Rieder HL. Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs. Int J Tuberc Lung Dis. 2018;22(3):239–45. doi: https://doi.org/10.5588/ijtld.17.0660.
Mirzayev F, Viney K, Linh NN, Gonzalez-Angulo L, Gegea M, Jaramillo E et al. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. Eur Respir J. 2021;57(6):2003300. doi: https://doi.org/10.1183/13993003.03300-2020.
Gibson J, Donnan E, Eather G. Management of rifampicin mono-resistant tuberculosis in Queensland, Australia: a retrospective case series. Respirol Case Rep. 2018;6(8):e00366. doi: https://doi.org/10.1002/rcr2.366.
Toman K, Frieden TR, WHO. Toman’s tuberculosis : case detection, treatment, and monitoring : questions and answers / edited by T. Frieden, 2nd ed. Geneva: WHO; 2004. Available from: https://apps.who.int/iris/handle/10665/42701.
WHO. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: WHO; 2014. Available from: https://apps.who.int/iris/handle/10665/130918.
Curry International Tuberculosis Center (CITC), California Department of Public Health Tuberculosis Control Branch. Drug-Resistant Tuberculosis: A Survival Guide for Clinicians,3rd edition/2022 Updates. San Francisco: University of California San Francisco, CITC; December 2022. Available from: https://www.currytbcenter.ucsf.edu/products/view/drug-resistant-tuberculosis-survival-guide-clinicians-3rd-edition.
WHO Regional Office for Europe. The role of surgery in the treatment of pulmonary tuberculosis and multidrug- and extensively drug-resistant tuberculosis. Geneva: WHO; 2014.
Fox GJ, Mitnick CD, Benedetti A, Chan ED, Becerra M, Chiang CY et al. Surgery as an adjunctive treatment for multidrug-resistant tuberculosis: an individual patient data meta-analysis. Clin Infect Dis. 2016;62(7):887–95. doi: https://doi.org/10.1093/cid/ciw002.
Marrone MT, Venkataramanan V, Goodman M, Hill AC, Jereb JA, Mase SR. Surgical interventions for drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2013;17(1):6–16. doi: https://doi.org/10.5588/ijtld.12.0198.
WHO Global Tuberculosis Programme. WHO operational handbook on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. Geneva: WHO; 15 December 2022. Available from: https://www.who.int/publications/i/item/9789240065116.
Upton CM, Steele CI, Maartens G, Diacon AH, Wiesner L, Dooley KE. Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB). J Antimicrob Chemother. 2022;77(6):1720–4. doi: https://doi.org/10.1093/jac/dkac067.
Tucker EW, Pieterse L, Zimmerman MD, Udwadia ZF, Peloquin CA, Gler MT et al. Delamanid central nervous system pharmacokinetics in tuberculous meningitis in rabbits and humans. Antimicrob Agents Chemother. 2019;63(10):e00913-19. doi: https://doi.org/10.1128/AAC.00913-19.
Alffenaar JWC, Akkerman OW, Kim HY, Tiberi S, Migliori GB. Precision and personalized medicine and anti-TB treatment: is TDM feasible for programmatic use? Int J Infect Dis. 2020;92S:S5–9. doi: https://doi.org/10.1016/j.ijid.2020.01.041.
Sturkenboom MG, Märtson AG, Svensson EM, Sloan DJ, Dooley KE, van den Elsen SHJ et al. Population pharmacokinetics and Bayesian dose adjustment to advance TDM of anti-TB drugs. Clin Pharmacokinet. 2021;60(6):685–710. doi: https://doi.org/10.1007/s40262-021-00997-0.
Migliori GB, Marx FM, Ambrosino N, Zampogna E, Schaaf HS, van der Zalm MM et al. Clinical standards for the assessment, management and rehabilitation of post-TB lung disease. Int J Tuberc Lung Dis. 2021;25(10):797–813. doi: https://doi.org/10.5588/ijtld.21.0425.
WHO. WHO guidelines on tuberculosis infection prevention and control, 2019 update. Geneva: WHO; 2019. Available from: https://apps.who.int/iris/handle/10665/311259.
Migliori GB, Nardell E, Yedilbayev A, D’Ambrosio L, Centis R, Tadolini M et al. Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe. Eur Respir J. 2019;53(6):1900391. doi: https://doi.org/10.1183/13993003.00391-2019.
Marks SM, Mase SR, and Morris SB. Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis. Clin Infect Dis. 2017;64(12):1670–7. doi: https://doi.org/10.1093/cid/cix208.
Linh NN, Viney K, Gegia M, Falzon D, Glaziou P, Floyd K et al. World Health Organization treatment outcome definitions for tuberculosis: 2021 update. Eur Respir J. 2021;58(2):2100804. doi: https://doi.org/10.1183/13993003.00804-2021.
Fox GJ, Menzies D. A review of the evidence for using bedaquiline (TMC207) to treat multi-drug resistant tuberculosis. Infect Dis Ther. 2013;2(2):123–44. doi: https://doi.org/10.1007/s40121-013-0009-3.
De Bus L, Depuydt P, Libbrecht L, Vandekerckhove L, Nollet J, Benoit D et al. Severe drug-induced liver injury associated with prolonged use of linezolid. J Med Toxicol. 2010;6(3):322–6. doi: https://doi.org/10.1007/s13181-010-0047-0.
Luque S, Muñoz-Bermudez R, Echeverría-Esnal D, Sorli L, Campillo N, Martínez-Casanova J et al. Linezolid dosing in patients with liver cirrhosis: standard dosing risk toxicity. Ther Drug Monit. 2019;41(6):732–9. doi: https://doi.org/10.1097/FTD.0000000000000665.
Published
How to Cite
License
Copyright (c) 2023 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
